Table 2 Summary of received treatments for Hematological Malignancies at the onset of COVID-19
n | % | |
|---|---|---|
Last/ongoing treatment strategy before COVID-19 | ||
Immunochemotherapy | 857 | 22.5 |
Targeted therapya | 607 | 16.0 |
Conventional chemotherapy | 597 | 15.7 |
No treatment | 538 | 14.1 |
Palliative/supportive measures | 226 | 6.0 |
Immunomodulators | 218 | 5.7 |
Allogeneic HSCT | 173 | 4.6 |
Anagrelide/Hydroxyurea | 145 | 3.8 |
Hypomethylating agents | 141 | 3.7 |
Immunotherapy only | 125 | 3.3 |
Autologous HSCT | 74 | 1.9 |
Unknown | 41 | 1.1 |
Other | 28 | 0.7 |
CAR-T | 21 | 0.6 |
Radiotherapy | 10 | 0.3 |
Summary of received treatmentb | ||
Chemotherapy | 3178 | 83.6 |
In the last month | 1979 | 52.1 |
In the last 3 months | 523 | 13.8 |
Treatment ended > 3 months | 631 | 16.6 |
Not stated | 45 | 1.2 |
Radiotherapy | 186 | 4.9 |
Allogeneic HSCT | 265 | 7.0 |
Autologous HSCT | 292 | 7.7 |
CAR-T | 24 | 0.6 |
Other strategies | 150 | 3.9 |
No treatment | 538 | 14.2 |